We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Official Guideline Summarizes Advances in Fungal Infections Diagnosis

By LabMedica International staff writers
Posted on 09 Sep 2019
Print article
Image: A micrograph showing a mycosis (aspergillosis). The Aspergillus (which is spaghetti-like) is seen in the center and surrounded by inflammatory cells and necrotic debris (Photo courtesy of Wikimedia Commons).
Image: A micrograph showing a mycosis (aspergillosis). The Aspergillus (which is spaghetti-like) is seen in the center and surrounded by inflammatory cells and necrotic debris (Photo courtesy of Wikimedia Commons).
An official clinical guideline on laboratory diagnosis of fungal infections in pulmonary and critical care medicine was released in a recent publication.

Timely diagnosis of fungal infections, which are of increasing incidence and importance in immunocompromised and immunocompetent patients, relies on appropriate use of laboratory testing in susceptible patients.

In this regard, a panel of 11 experts in pulmonary and critical care, infectious disease, and invasive procedures appointed by the American Thoracic Society (New York, NY, USA) conducted a systematic review of medical studies on diagnosing fungal infections that had been published from 1980 to April 2016. The resulting official guideline covered the diagnosis of invasive pulmonary aspergillosis, invasive candidiasis, and the three most common endemic mycoses: blastomycosis, coccidioidomycosis, and histoplasmosis.

In particular, the panel addressed four clinical questions that clinicians face when they care for patients with suspected fungal infections: 1) Is serum and/or bronchoalveolar lavage (BAL) galactomannan (GM) testing sufficiently accurate to guide therapeutic decisions in place of histopathology and/or fungal culture in patients with impaired immunity suspected of having invasive pulmonary aspergillosis (IPA)? 2) Should diagnosis of suspected aspergillus infections in severely immunocompromised patients be based on the application of polymerase chain reaction (PCR)? 3) In critically ill patients with suspected invasive candidiasis, is the (1→3)-β-D-glucan (BDG) assay alone sufficient for diagnostic decision-making? 4) Should diagnosis of the common endemic mycoses (i.e., histoplasmosis, blastomycosis, coccidioidomycosis) be based on serology and antigen testing?

The guideline included specific recommendations for dealing with these situations, stressing that rapid, accurate diagnosis of fungal infections relied on appropriate application of laboratory testing, including antigen testing, serological testing, and PCR-based assays.

“Our goal was to produce a concise evidence-based clinical practice guideline that will help clinicians use newer laboratory methods in diagnosis of these important infections,” said guideline co-chair Dr. Andrew H. Limper, professor of pulmonary medicine at the Mayo Clinic (Rochester, MN, USA). “This guideline summarizes the best available evidence on the use of common laboratory tests to diagnose invasive pulmonary aspergillosis, invasive candidiasis, as well as histoplasmosis, blastomycosis, and coccidioidomycosis.”

“As always, application of any guideline information must be integrated into the overall clinical context for an individual patient when confirming the diagnosis of invasive fungal infection,” said Dr. Limper.

The guideline was published in the September 1, 2019, issue of the Journal of Respiratory and Critical Care Medicine.

Related Links:
American Thoracic Society
Mayo Clinic

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.